February 8, 2021
The FDA has granted De Novo authorization to what will be the first device treatment for obstructive sleep apnea (OSA) that is used while the patient is awake.
Called eXciteOSA, the prescription tongue muscle stimulation device is intended for those aged 18 years or older to reduce mild sleep apnea and snoring. Patients use the device for 20 minutes once per day over a six-week period, and...
April 7, 2020
Brisbane-based ResApp, which creates smartphone apps for the diagnosis and management of respiratory diseases, last week announced its plans to launch SleepCheck, an at-home obstructive sleep apnoea (OSA) screening app. The company said it plans to launch SleepCheck for iOS on the App Store in the United Kingdom and Australia in the second quarter of this calendar year, with availability in...
July 5, 2016
Sleep apnea device developer NightBalance announced today it has raised $13.9 million (EU €12.5 million) in second round funding led by INKEF Capital and Gilde Healthcare Partners. The Dutch company will use the funds to further advance the rollout of its Sleep Position Trainer (SPT) device and enter the US market.
In addition to the funding, NightBalance also added four new members to its...
April 25, 2013
Philips Respironics has included wireless connectivity in its CPAP (continuous positive airway pressure) machines for people with obstructive sleep apnea for going on four years now. The machines have transmitted data to healthcare providers who could remotely check-in on their patients and make adjustments to their machines and therapy as needed. With the launch of a new app, called SleepMapper...
January 18, 2012
This month at the Consumer Electronics Show (CES) NovaSom, which makes home tests for obstructive sleep apnea (OSA) unveiled an FDA-cleared OSA test kit that leverages Verizon Wireless' cellular network to wirelessly collect and transfer sleep data up to a cloud-based platform for physician interpretation and diagnosis. Last summer the company scooped up $35 million in new funding.